Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

CNS-fo­cused Su­per­nus Phar­ma­ceu­ti­cals $SUPN re­port­ed pos­i­tive da­ta from keen­ly watched twin stud­ies test­ing its non-stim­u­lant AD­HD drug in chil­dren on Thurs­day, but the re­sults sug­gest­ed the treat­ment does not have a leg up over an ex­ist­ing gener­ic drug on the mar­ket.

Shares of the Rockville, Mary­land based-com­pa­ny were down about 13% in ear­ly trad­ing.

Two dos­es of the drug SPN-812 were test­ed against a place­bo in each study —  100mg/200mg in study P301, and 200mg/400 mg in study P303.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER